Expert Answers to Questions on PARP Inhibitor Combinations in Prostate Cancer

In this episode,  Wassim Abida, MD, PhD; Joaquin Mateo, MD, PhD; and Charles J. Ryan, MD, answer questions from an audience of healthcare professionals on topics related to prostate cancer and PARP inhibition including:  

• Germline and somatic mutation testing
• PARP inhibition in earlier stage disease
• PARP inhibitors plus AR-targeted therapy after progression on AR-targeted therapy
• PARP inhibition in taxane-sensitive patients

Presenters:

Wassim Abida, MD, PhD
Assistant Member
Assistant Attending Physician
Genitourinary Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Joaquin Mateo, MD, PhD
Group Leader
Prostate Cancer Translational Research
Vall d'Hebron Institute of Oncology
Attending Physician
Medical Oncology
Vall d'Hebron University Hospital
Barcelona, Spain

Charles J. Ryan, MD
Professor of Medicine
B.J. Kennedy Chair in Clinical Medical Oncology
Director, Division of Hematology, Oncology and Transplantation
Department of Medicine
University of Minnesota
Oncologist
Division of Hematology, Oncology and Transplantation
University of Minnesota Health Clinics and Surgery Center
Minneapolis, Minnesota

Link to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:
https://bit.ly/3h1T5oR

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.